Omeros Logo     Print Page  |  Close Window

Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.18 (0.94%)
Data as of 10/20/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
10/20/17Report of Successful OMS721 Treatment of Patient with Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-versus-Host Disease Presented at EBMT Annual Meeting
-- Results May Expand Target for Omeros’ Planned Phase 3 Program in HCT-TMA -- SEATTLE--(BUSINESS WIRE)--Oct. 20, 2017-- Omeros Corporation (NASDAQ: OMER) today announced the presentation of a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and graft-versus-host disease (GvHD), which both resolved following OMS721 treatment. This case was presented this morning at t... 
 Printer Friendly Version
10/16/17Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation
SEATTLE--(BUSINESS WIRE)--Oct. 16, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data will be presented from the company’s Phase 2 clinical trial of OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), for the treatment of thrombotic microangiopathies (TMAs). The presentation will be part of the “Crash course on diagnosis and treatment of noninfectious complications a... 
 Printer Friendly Version
10/05/17Omeros Announces Settlement of Infringement Suit Against ANDA Filer Par
--Par Confirms Validity of OMIDRIA Patents and Agrees Not to Market a Generic Version of OMIDRIA Until 2032-- SEATTLE--(BUSINESS WIRE)--Oct. 5, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that it entered into a settlement agreement with Par Pharmaceutical, Inc. and its subsidiary Par Sterile Products, LLC (Par), resolving Omeros’ patent litigation against Par. The litigation concerned Par’s filing of an Abbreviated New Drug Applic... 
 Printer Friendly Version
08/23/17Omeros Responds to Story
SEATTLE--(BUSINESS WIRE)--Aug. 23, 2017-- Omeros Corporation (NASDAQ:OMER) stated today that it continues to pursue legal action to hold responsible those behind a series of defamatory reports about the company posted online under the pseudonym “Art Doyle,” an entity or group that self-identifies as having a short position in Omeros’ stock. Because of its ongoing legal action, including a number of steps aimed at unmasking the identity of the indi... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2016 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.